StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s): SZLSF

Healthcare Biotechnology

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.

TSX:SZLS - Post by User

StageZero Life Sciences Ltd > Updated Price Target from Clarus (Noel Atkinson)

<< Previous

Bullboard Posts

Next >>

Comment by NewToInvesting7on Dec 09, 2020 10:19am

204 Views

Post# 32066695

RE:Updated Price Target from Clarus (Noel Atkinson)

One other thing that I failed to mention - The Dec. 8 Morningstar report on SZLS, currently shows a Fair Value of a share to be C$1.19.

(Apologies for the follow-up, but I thought that I could edit my post to add the adove. Clearly I was worng).

NewToInvesting7 wrote: Not sure whether this has been posted yet, but thought that I would make mention of Noel's change in price target for SZLS.

The TD Webbroker website is showing that Noel Atkinson has maintained his buy rating for SZLS, and has change his price target on 12/08/2020 (Dec. 8), from C$4 to C$5.13

Cheers